OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. - Melanoma/Skin Cancers - Melanoma/Skin Cancers - 2013 ASCO Annual Meeting
5em"> 1csg: THREE-DIMENSIONAL STRUCTURE OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR 2gmf: HUMAN GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR v t e Cytokines, glycoproteins: colony-stimulating factors CFU-GEMM Interleukin 3 CFU-GM Granulocyte macrophage colony-stimulating factor Granulocyte.